Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Abstract:

HDT-AHCT is a standard and potentially curative therapy for patients with high risk, chemosensitive lymphomas. Improvements in supportive care and HCT practices have led to increasing use of HDT-AHCT worldwide particularly in elderly and more comorbid patients at higher risk of complications. However, HDT is associated with severe regimen-related toxicities (SRRT) which lead to considerable symptom burden and in some cases, life-threatening organ toxicities. Moreover, the risk of SRRT is a significant concern and may lead to patients being denied a potentially curative therapy. Although SRRT can affect many organs, the most commonly affected are those with high cell turnover, including the hematopoietic system and oral-gastrointestinal tract (oral/GI tract). While the hematopoietic system is rescued by AHCT, there are no effective therapies to substantially reduce SRRT.

AB-205 is a novel experimental engineered-cell therapy intended to reduce SRRT associated with HDT-AHCT. AB-205 contains clinical-grade, allogeneic E4ORF1⁺ CD31⁺ umbilical vein endothelial cells, or ‘universal’ E-CEL® cells, and has been shown to accelerate the recovery of the vascular niches in various organs through autocrine and juxtacrine mechanisms of action on resident tissue capillary endothelial cells and resident progenitors in preclinical studies. It also has a beneficial effect in chaperoning exogenously administered stem cells.

Here we report results of a Phase I study of AB-205 in adults with lymphoma undergoing HDT-AHCT.

62^nd ASH Annual Meeting and Exposition – December 5, 2020

Michael Scordo, MD¹, Lihua E Budde, MD, PhD², Mehrdad Abedi, MD³, Carolyn Mulroney, MD⁴, Bita Fakhri, MD, MPH⁵, Attaphol Pawarode, MD PhD⁶, Bhagirathbhai Dholaria, MBBS⁷, Edward Kavalerchik, MD⁸, Sanjay K. Aggarwal, MD^9*, Muzaffar H. Qazilbash, MD¹⁰, Paul Finnegan, MD¹¹ and Sergio A. Giralt, MD^12,13

¹Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NY, ²T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, ³UC Davis Medical Center, Sacramento, CA, ⁴UCSD Moores Cancer Center, La Jolla, CA, ⁵Division of Hematology and Oncology, University of California, San Francisco, CA, ⁶Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI, ⁷Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical center, Nashville, TN, ⁸Clinical Development, Angiocrine Bioscience, San Francisco, CA, ⁹Clinical Development, Angiocrine Bioscience, San Diego, CA, ¹⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, ¹¹Angiocrine Bioscience, San Diego, CA, ¹²Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, ¹³Memorial Sloan Kettering Cancer Center, New York, NY

Go to ASH Meeting -2020